@invitewellnessllc's testosterone therapy claims checked

What did @invitewellnessllc actually say?

The creator responded to a viewer named Thomas, who reported his total testosterone went from 305 to 299 ng/dL and his free testosterone went from 3.5 to 5.9 pg/mL after starting 50mg/week of testosterone cypionate (the creator mispronounces this repeatedly as "testosterone sepenate"). The core argument: exogenous testosterone signals the body to suppress its own production, so you cannot simply add injected testosterone on top of your baseline. At a low dose like 50mg/week, that suppression can outpace what the injection contributes, leaving the patient in a net deficit. The creator concludes that the current protocol is "not doing you any good" and is, in fact, "causing harm."

Does the science back this up?

The suppression mechanism is real and well-documented. The hypothalamic-pituitary-gonadal axis runs on negative feedback: exogenous androgens reduce GnRH output, LH and FSH fall, and testicular production drops. Bhasin et al. (2001, New England Journal of Medicine) showed this dose-dependent suppression clearly in healthy men. What the creator underplays is that Thomas's free testosterone actually rose from 3.5 to 5.9 pg/mL. Free testosterone is the biologically active fraction. Ramasamy et al. (2014, Journal of Urology) found free testosterone often predicts symptomatic relief better than total testosterone. The creator's narrative that nothing good happened for Thomas is incomplete. Whether 50mg/week is an inadequate dose depends on SHBG levels, injection timing relative to blood draw, and individual metabolism, none of which were addressed.

What did they get wrong (or right)?

Credit where it is due: the creator correctly identifies that exogenous testosterone suppresses endogenous production. This is accurate physiology, and it is something patients are frequently not told before starting TRT. The claim that total testosterone barely moved (305 to 299) while on exogenous testosterone does warrant a clinical conversation about dose adequacy or protocol adherence.

Where the creator oversimplifies: they treat the free testosterone increase as irrelevant without saying so directly. A jump from 3.5 to 5.9 pg/mL in free T is not nothing. Whether it is enough depends on the lab's reference range and whether Thomas is symptomatic. The creator also makes a categorical statement that this protocol is "causing harm" without any clinical qualification. That is a strong claim. Subclinical suppression of endogenous production at low-dose TRT is a documented pharmacological effect, but labeling it harm for every patient at every dose crosses from education into overstatement. Mulhall et al. (2018, Journal of Urology, AUA guidelines) outline that treatment targets should be individualized, not applied as universal thresholds.

What should you actually know?

If you are on TRT and your total testosterone has not risen meaningfully, several variables matter before concluding the dose is wrong. First, when was blood drawn relative to injection? Testosterone cypionate peaks roughly 24 to 48 hours post-injection and troughs before the next dose. A trough draw will always look low. Second, SHBG (sex hormone-binding globulin) determines how much testosterone is free versus bound. High SHBG can suppress free T even when total T looks acceptable, and vice versa. Third, 50mg/week is at the lower end of typical TRT dosing, but some patients respond well to it, particularly those with lower SHBG or higher sensitivity. Pastuszak et al. (2017, Urology) note that individualized dosing based on symptoms and lab timing produces better outcomes than fixed-dose protocols. The creator is right that a stagnant or declining total testosterone on TRT needs clinical review. But "causing harm" requires more information than two data points from a comment section.